It's #kidneywk but it also happens to be #STEMDay. The curiosity, drive, and creativity of the next generation of nephrologists and researchers are fueling the future of kidney science and patient care. Watching early-career scientists present their work at #ASN25 and challenge

Today at ASN we presented new data from the Phase 3 DUPLEX Study in #FSGS. Read the press release https://t.co/LXvsIISfSC

Don’t miss our presentations this week at American Society of Nephrology's 2025 #KidneyWk #ASN25 in Houston, Texas. We're excited to share new data and analyses from our work in #IgAnephropathy and #FSGS. We are proud to be here with the nephrology professional community,

Today we reported our third quarter earnings and provided a corporate update. Press Release: https://t.co/gL0y3tD3eZ

Today we announced that we will present 11 abstracts, including a late-breaking poster presentation, at the upcoming American Society of Nephrology #ASN25 #KidneyWk 2025 in Texas, November 6-9. For more information, please read the press release: https://t.co/3wFmSgN5Kh

Today we announced with our commercial partner CSL Vifor our recognition of the recent publication of the updated clinical practice guidelines for the treatment of IgA nephropathy (IgAN), Kidney Disease: Improving Global Outcomes (KDIGO) 2025 Clinical Practice Guideline for the

Aloha to everyone from the 2nd annual live @GlomCon conference. We are excited to share data from our SPARTAN, SPARTACUS and DUPLEX trials, and catch up with fellow #RareKidneyDisease specialists. #GlomConHawaii #InRareForLife

We’ve arrived to Charleston for the International Conference on Endothelin where we’re pleased to share numerous presentations on our work in FSGS and IgA nephropathy. At Travere, we are committed to making a difference in the lives of people with #RareKidneyDisease.

We are in Prague with #IgAnephropathy experts from around the world at the #iigann2025 meeting. This week we'll present 3 abstracts from our clinical studies in #IgAnephropathy, as well as a preclinical presentation on IgAN pathogenesis.

Travere is pleased to support a virtual Glomcon seminar on September 14. Visit https://t.co/bLRXumq0RW for more information about the medical education event.

Today we announced that the FDA has informed us that following further review of the supplemental sNDA for FILSPARI® (sparsentan) in #FSGS, an advisory committee is no longer needed. https://t.co/6i9hpG8jdj

We are delighted to join metabolic experts worldwide at the #ICIEM2025 congress in Kyoto this week where we are sharing more from the Phase 1/2 pegtibatinase clinical study in patients with classical #homocystinuria. #InRareForLife

Today we announced that we will present 2 oral presentations on our work in classical #homocystinura at the International Congress of Inborn Errors of Metabolism, September 2-6, 2025, in Kyoto, Japan. https://t.co/OETcKQY0Jn

Today we announced that the FDA has approved updated Risk Evaluation and Mitigation Strategy (REMS) labeling for FILSPARI® (sparsentan) https://t.co/xQ1vyqhBOY

Today we reported our second quarter 2025 financial results and provided a corporate update. Press Release: https://t.co/sByqHmQFVX

At the International Podocyte Conference, we will share new data on sparsentan, including preclinical data evaluating biomarkers of disease progression in #IgAN. Check out all our presentations at https://t.co/bwuRhCVvwl. #InRareForLife #PodocyteConference2025

Today we announced that we will present 3 abstracts on the effect of FILSPARI (sparsentan) in #RareDidneyDisease at the upcoming International Podocyte Conference in Hamburg, Germany, June 10-13, 2025. #InRareForLife #PodocyteConference2025  https://t.co/bwuRhCW3lT

On #FSGSAwarenessDay, we’re announcing "Play it Forward" - our new campaign elevating the voices and talents of the FSGS community! Learn more: https://t.co/TFhtFqTDpf #PlayitForwardFSGS

At @ERAkidney this week in Vienna, we will share 7 presentations, including new data from the Phase 2 SPARTACUS Study of sparsentan in combination with SGLT2i therapy. https://t.co/ZIM4cbZ7Nl #InRareForLife #ERA25

Today we announced that we will present 7 abstracts at the upcoming @ERAkidney Congress in Vienna, Austria, June 4-7, 2025. #InRareForLife #ERA25 https://t.co/ZIM4cbZFCT